Trastuzumab treatment alone was inactive in PAC120 xenografts and in HID28 variant, distinguishing our model from the CWR22 prostate cancer xenograft model, which overexpresses HER2 and is sensitive to Trastuzumab (Agus et al, 1999). This evidence concerns the gene ERBB2 and prostate cancer.